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Abstract
Laboratory tests that can distinguish recent from long-term HIV infection are used to estimate 
HIV incidence in a population, but can potentially misclassify a proportion of long-term HIV 
infections as recent. Correct application of an assay requires determination of the proportion false 
recents (PFRs) as part of the assay characterization and for calculating HIV incidence in a local 
population using a HIV incidence assay. From April 2009 to December 2010, blood specimens 
were collected from HIV-infected individuals attending nine outpatient clinics (OPCs) in Vietnam 
(four from northern and five from southern Vietnam). Participants were living with HIV for ≥1 
year and reported no antiretroviral (ARV) drug treatment. Basic demographic data and clinical 
information were collected. Specimens were tested with the BED capture enzyme immunoassay 
(BED-CEIA) and the Limiting-antigen (LAg)-Avidity EIA. PFR was estimated by dividing the 
number of specimens classified as recent by the total number of specimens; 95% confidence 
intervals (CI) were calculated. Specimens that tested recent had viral load testing performed. 
Among 1,813 specimens (north, n = 942 and south, n = 871), the LAg-Avidity EIA PFR was 1.7% 
(CI: 1.2–2.4) and differed by region [north 2.7% (CI: 1.8–3.9) versus south 0.7% (CI: 0.3–1.5); p 
= .002]. The BED-CEIA PFR was 2.3% (CI: 1.7–3.0) and varied by region [north 3.4% (CI: 2.4–
4.7) versus south 1.0% (CI: 0.5–1.2), p < .001]. Excluding specimens with an undetectable VL, the 
LAg-Avidity EIA PFR was 1.2% (CI: 0.8–1.9) and the BED-CEIA PFR was 1.7% (CI: 1.2–2.4). 
The LAg-Avidity EIA PFR was lower than the BED-CEIA PFR. After excluding specimens with 
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an undetectable VL, the PFR for both assays was similar. A low PFR should facilitate the 
implementation of the LAg-Avidity EIA for cross-sectional incidence estimates in Vietnam.
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Introduction
The first case of HIV infection in Vietnam was reported in 1990. An estimated 256,000 
people were living with HIV in Vietnam in 2014.1 Currently the prevalence of HIV infection 
in Vietnam is less than 1% and concentrated within key populations at risk, including 
injection drug users (IDU), female sex workers (FSW), and men who have sex with men 
(MSM). Between 2000 and 2014, the estimated number of people living with HIV more than 
doubled from 100,000 to 256,000.1,2 Although significant progress has been made in 
responding to the HIV epidemic in the country, international donor contributions are 
decreasing and much work is still needed to reach Vietnam’s goal of ending AIDS by 2030.
Identifying subpopulations at high risk for new HIV infection is critical for halting the 
transmission of HIV. Currently most HIV programs worldwide track the epidemic by 
monitoring trends in HIV prevalence in a population. Although prevalence is an important 
measure, it provides a limited understanding of the most recent spread of infection or HIV 
incidence. HIV incidence can identify current transmission dynamics to effectively target 
interventions and allocate resources. In addition, HIV incidence provides data for evaluating 
the success of prevention programs.3 However, obtaining HIV incidence rates have been 
challenging. Longitudinal prospective cohort studies are the gold standard for estimating 
HIV incidence, yet they are lengthy, costly, complicated, and may be unrepresentative of the 
general population due to self-selective enrollment of participants, among other issues.3 In 
response, laboratory assays were developed that can distinguish recent from long-term HIV 
infection based on immunologic markers of disease progression and can be applied to cross-
sectional surveys to estimate HIV incidence.4 The World Health Organization’s (WHO) 
guidelines for estimating HIV incidence in the population have incorporated the use of one 
or more tests as part of an algorithm to estimate cross-sectional HIV incidence.3
A significant limitation of current HIV incidence laboratory assays is that they overestimate 
HIV-1 incidence by misclassifying a proportion of individuals with long-term infection 
(defined in this study as infection ≥1 year) as recent infection, which can lead to errors in 
incidence estimations.4,5 The proportion of individuals with long-term infection that 
misclassify as recent infection on the incidence assay is termed in this study as the assay’s 
proportion false recent (PFR). Because the PFR has been shown to vary significantly by 
population, HIV subtype,6 HIV epidemic phases,7 individual immune status, and 
antiretroviral (ARV) use,8–10 current guidance for estimating incidence recommends that 
countries determine a local PFR that can be incorporated into the incidence formula for 
calculating HIV incidence.3,11 Low viral loads among HIV-infected persons as a result of 
ARV treatment and among those who naturally maintain an undetectable viral load in the 
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absence of treatment (also known as “elite controllers”) will misclassify as false recent on 
incidence assays that rely on HIV antibodies to determine recent infection. Experts in the 
field of HIV incidence assay development recommend that a PFR for a HIV incidence assay 
not exceed 2% to produce reliable incidence estimates.6
At the time of this study, the BED capture enzyme immunoassay (BED-CEIA) was the only 
commercially available assay, and the Limiting-antigen (LAg)-Avidity EIA was in 
development. However, the new single-well LAg-Avidity EIA was recently described to 
distinguish recent from longstanding HIV infections for the purpose of estimating incidence 
in cross-sectional populations.12 Briefly, the BED-CEIA measures the proportion of anti-
HIV IgG relative to total IgG. As anti-HIV IgG increases with time, a lower proportion of 
anti-HIV IgG to total IgG would indicate a recent infection.13,14 In contrast, the LAg-
Avidity EIA determines the avidity or “binding strength” of the HIV-1 antibodies. Because 
antibodies mature and become more specific over time, antibodies from a recently infected 
individual would have a weaker binding strength to the virus than an individual infected for 
a longer duration.12,15 While the BED-CEIA has shown relatively high PFR in a 
standardized multiclade specimen set derived from persons with longstanding HIV infection, 
the PFR for the LAg-Avidity EIA has been shown to be substantially lower in the same 
samples.16 However, subtype-specific PFR for clade A/E, which predominates in South East 
Asia, was not included in this evaluation. The purpose of this study was to determine the 
applicability of the LAg-Avidity EIA and the BED-CEIA in Vietnam by determining the 
PFR for each assay.
Methods
Study population
This cross-sectional study was conducted from April 2009 to December 2010 in nine 
purposively selected outpatient clinics (OPCs) in the northern (n = 4) and southern regions 
(n = 5) of Vietnam. Eligible participants were 18 years of age or older, had a confirmed HIV 
infection for ≥1 year based on initial HIV diagnosis date, and self-reported no ARV use. A 
sample size of 1,917 specimens was calculated using the BED-CEIA parameters and 
assuming an expected PFR of 5% (based on previously published studies), measured with 
precision of 1% (precision was defined as half the width of the confidence interval), and a 
refusal rate of 5%.13,17–19
Specimen collection
After informed consent was provided, a venous blood sample was collected from each 
individual, and a chart review was conducted to obtain data on demographics, HIV risk 
factors, opportunistic infections (OIs), and CD4 count. CD4 count was based on the most 
recent CD4 result documented in the medical chart at the time of enrollment. The whole 
blood was processed into plasma aliquots by centrifuging the sample at 3,000 rpm for 10min 
and stored at −70°C.
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Laboratory testing for recent HIV-1 infection
Specimens were tested with the LAg-Avidity EIA and BED-CEIA according to the 
manufacturer’s instructions (both manufactured by Sedia BioSciences, Portland, Oregon). 
Normalized optical density (ODn) cutoffs of 1.5 for LAg-Avidity EIA and 0.8 for 
BED_CEIA were used to distinguish recent from long-term HIV infection. Specimens with 
final ODn values at or below the ODn cutoff for each respective assay were classified as 
recent infections, while those with values above the ODn cutoff were classified as long-term 
infections. BED-CEIA testing was conducted by the Vietnam National Institute of Hygiene 
and Epidemiology (NIHE) and the Ho Chi Minh City Pasteur Institute (HCMC PI). The 
LAg-Avidity EIA testing was performed at the Centers for Disease Control and Prevention 
(CDC) in Atlanta, Georgia, where specimens were tested in duplicate runs to increase 
confidence of results irrespective of their ODn levels. The mean ODn value was used for 
final classification. All specimens classified as recent with ODn values lower than 0.4 and 
0.3 by the LAg-Avidity EIA and BED-CEIA, respectively, were further tested by western 
blot to confirm HIV seropositivity at the CDC. All specimens that classified as recent and 
that had sufficient volume underwent additional testing, including HIV subtyping, viral load 
analysis, and detection of ARV drugs at the CDC.
HIV-1 subtyping
Subtyping was performed on a random sample of 100 specimens. Nucleic acid was isolated 
from 200 µL plasma samples using the NucliSENS® system for lysis and extraction 
(BioMerieux). Nucleic acid was eluted in 25 µL of NucliSENS Extraction Buffer 3 and 
either immediately used for RT-PCR or stored at −80°C until use. Subtyping of the HIV-1 
envgp41 gene was performed following the procedure of a broadly sensitive CDC in-house 
assay as described in detail previously with the exception of using envgp41 primers as 
described before.20,21 The ReCALL software program was used to edit the raw sequences 
and generate consensus sequences.22
HIV-1 subtyping for the newly obtained sequences was performed using the REGA HIV-1 
Genotyping Tool.23 Phylogenetic analyses were further conducted using neighbor-joining 
method included in the MEGA 5 for sequences with unclassifiable subtypes.23 Reference 
sequences were obtained from the Los Alamos HIV Database (www.hiv.lanl.gov). The 
stability of the tree nodes was assessed by bootstrap analysis using 1,000 replicates. 
Bootstrap values ≥70% were considered significant.24
Viral load testing
Quantification of plasma RNA was determined using the Abbott RealTime m2000 platform. 
Due to low sample volumes, plasma samples were diluted fourfold in serum base matrix, 
resulting in a limit of detection of 600 copies/mL. Specimens with viral load <1,000 
copies/mL were considered to have a low viral load.
Detection of ARV drugs
Specimens that classified as recent infection by either assay were tested for the detection of 
antiretroviral drugs to ensure that individuals were indeed ARV-naive. Antiretroviral (ARV) 
drugs from first-line regimens in Vietnam [Nevirapine (NVP), Efavirenz (EFV), and 
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Lamivudine (3TC)] were measured in plasma simultaneously by high-performance liquid 
chromatography– tandem mass spectrometry (HPLC-MS/MS). Drugs from 100 µL of 
plasma were extracted with 370 µL of acetonitrile containing 270 ng/mL each of the internal 
standards [NVP-d5 (TRC) for NVP, EFV-d4 (TRC) for EFV, and FTC-13C 15 N2 (Moravek 
Biochemicals and Radiochemicals) for 3TC]. Protein precipitates were removed by 
centrifugation, and the liquid extracts were transferred to the wells of a 96-well 
polypropylene plate and then evaporated to almost dryness in a vacuum concentrator and 
reconstituted with 150 µL of mobile phase A (0.1%formic acid in water). A volume of 15 µL 
of the final processed sample was injected into a Shimadzu Prominence HPLC system, 
connected to a model 3200 QTRAP mass spectrometer (AB Sciex) that was used to detect 
the compounds of interest. Data were processed using Analyst 1.5.1 (AB Sciex). The limit 
of quantification (LOQ) was 25 ng/mL for NVP and 10 ng/mL for both EFV and 3TC.
Calculation of PFR
The PFR was estimated by dividing the number of specimens testing recent on the assay by 
the total number of specimens in the study population. The PFR was calculated for each 
assay by select demographic and clinical characteristics and stratified by geographic region 
(northern versus southern) and clinic. We used the term PFR instead of false recent rate 
(FRR) as the latter implies a time factor which was not addressed in this study. Statistical 
significance was assessed using t-test, chi-square, McNemar, and Fisher’s exact tests, where 
indicated. p-values of <.05 were considered statistically significant. Confidence intervals 
were calculated using the Wilson score interval procedure. Multivariate analysis was not 
conducted as the study was not powered for such analysis. Data forms were double entered 
into EpiData by NIHE and HCMC PI. Data analyses were conducted using Stata version 
10.0 (StataCorp) and SAS version 9.2 (SAS Institute).
Ethical considerations
The protocol was reviewed and approved by the Institutional Review Boards of CDC and 
NIHE. Because these incidence assays may not be accurate at the individual level and are 
approved for surveillance use only, individual-level data were not linked to any identifiers 
and test results were not returned to participants. Specimens and data forms were labeled 
with unique study identification (ID) numbers, which were used to merge clinical data and 
incidence assay results.
Results
Characteristics of the study population
A total of 1,935 samples were collected (north, n = 1,030; south, n = 905). After excluding 
specimens with missing data, duplicates, and from individuals not meeting the inclusion 
criteria, including those who were classified as recent but were positive for ARV drugs, the 
final sample size for analysis was 1,813.
Table 1 shows the demographic, clinical, and risk factor characteristics of the population 
enrolled in the study. There were regional differences in the age distribution (north: 30.6% 
were aged ≥35 years versus south: 16.2%); CD4 cell count (north: 28.5% had CD4 count 
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<200 cells/mm3 compared to south: 15.8%); and duration of HIV infection (north: 30.9% 
had documented HIV infection >3 years compared to south: 11.5%). There were limited data 
on OIs; however, the most common documented OI was TB (11.2% of the study 
population).
Determination of PFRs
Overall, 31 of 1,813 specimens (1.7%: CI: 1.2–2.4) were classified as recent by the LAg-
Avidity EIA (Table 2), and 41 (2.3%: CI: 1.7–3.1) were classified as recent by the BED-
CEIA. Twenty-four (77.4%) of 31 LAg-recents were also recent by the BED-CEIA; seven 
specimens testing recent on the LAg-Avidity EIA did not test as recent on the BED-CEIA. 
All specimens classified as false recent by either LAg-Avidity EIA or BED-CEIA were 
recombinant subtype CRFO1_AE. The LAg-Avidity EIA or BED-CEIA PFRs were not 
statistically significantly different (p-value .06).
Analyses of PFRs
Table 3 summarizes the BED-CEIA PFR, by selected demographic and clinical 
characteristics, stratified by region. Thirty-two of 942 (3.4%, CI: 2.4–4.7) specimens from 
the north were false recent compared to 9 of 873 (1.0%, CI: 0.5–1.2) specimens from the 
south (p < .001). Within northern specimens, the BED-CEIA PFR was similar between sex 
(3.4% and 3.5% for specimens from men and women, respectively), while within southern 
specimens, more specimens from women (1.7%) were classified as false recent compared to 
those from men (0.2%). The differences in PFR by clinical characteristics and risk groups 
were not significant, and the differences in PFR between OIs were not analyzed due to zero 
cells.
Table 4 summarizes the PFR for LAg-Avidity EIA and by select demographic and clinical 
characteristics, stratified by region. Twenty-five of 942 (2.7%, CI: 1.8–3.9) specimens from 
the north misclassified as recent compared to 6 of 871 (0.7%, CI: 0.3–1.5) from the south (p 
= .002). There were no statistically significant differences in demographic and clinical 
characteristics between regions. However, specimens from individuals living with HIV for 
1–2 years had a higher proportion of misclassified specimens (2.0% vs. 1.5% among those 
infected >2 years).
For both assays, the PFR differed significantly by region with northern clinics having a 
higher PFR on both assays (Table 2). The PFR for both assays differed significantly among 
the northern clinics (p < .05, Fig. 1). The BED-CEIA PFR for northern clinics B (5.8%; CI: 
3.2–10.3) and C (4.2%; CI: 2.6–6.7) was high compared to northern clinics A (1.5%; CI: 
0.6–3.8) and D (1.7%; CI: 0.5–5.8). Specimens from northern clinic B (6.3%; CI: 3.6–11.0) 
had a higher LAg-Avidity EIA PFR compared to northern clinics A (0.4%; CI: 0.1–2.1), C 
(3.1%; CI: 1.8–5.4), and D (0.8%; CI: 0.2–4.5). The southern clinics had a similar PFR for 
both the LAg-Avidity EIA and BED-CEIA (p > .1).
Residual PFR
Among false-recent specimens, 10 specimens on BED-CEIA and 9 specimens on LAg-
Avidity EIA had HIV-1 RNA <1,000 copies/mL (low viral load, Fig. 2). After excluding 
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specimens with low viral load, the residual PFR for BED-CEIA was 1.6% (CI: 1.2–2.4) and 
for LAg-Avidity EIA was 1.2% (CI: 0.8–1.9) and not significantly different. Regionally, the 
residual BED-CEIA PFR was 2.0% (CI: 1.3–3.2) for the north and 0.3% (CI: 0.1–1.0) for 
the south. Similarly, the residual LAg-Avidity EIA PFR was 2.8% (CI: 1.9–4.0) for the north 
and 0.6% (CI: 0.3–1.4) for the south.
Discussion
This is the first study to estimate the PFRs in Southeast Asia for both the LAg-Avidity EIA 
and BED-CEIA from the same population. Although there was no statistically significant 
difference between the two assays, the point estimates for the LAg-Avidity EIA PFR were 
lower than the BED-CEIA, which complements previous demonstrations of improved 
performance characteristics of the LAg-Avidity EIA compared with the BED-CEIA.16,25 
The better performance of LAg-Avidity EIA is likely attributed to the design of the assay to 
measure HIV antibody avidity compared to the BED-CEIA, which is a capture EIA that 
measures the proportion of anti-HIV IgG to total IgG.
After accounting for low viral loads, the PFR decreased to 1.2% for the LAg-Avidity EIA 
and 1.7% for the BED-CEIA. Both the LAg-Avidity EIA and the BED-CEIA PFR were 
consistent with recent literature.26,27 The BED-CEIA PFR is the same as was reported from 
samples collected only from HCMC in southern Vietnam, however, was lower than 
previously reported in other populations.27–30 The LAg-Avidity EIA was lower than the 
AxSYM avidity index assay FRR of 2.7% from the HCMC study.27 The difference in PFR 
after excluding individuals with low viral loads demonstrates how individuals with long-
term infection who are elite controllers with naturally low or undetectable viral loads or 
potential individuals on ARV therapy who have low antibody levels can misclassify as recent 
on antibody-based assays.5,31,32 Therefore, to obtain accurate incidence estimates using 
current incidence assays, misclassification from low viral loads should be expected and 
accounted for in a recent infection testing algorithm. Although a residual PFR may still be 
present after these adjustments, in the context of Vietnam, given that the level of the PFR fell 
within the WHO recommended threshold (<2%), further adjustments may not be needed.
For example, we demonstrate the impact of the LAg-Avidity PFR on HIV incidence 
estimates in a key population at high risk for HIV exposure in Vietnam, persons who inject 
drugs (PWID) using a hypothetical example based on epidemiological data in this 
population.33 For this hypothetical example, the MDRI estimates were not adjusted to 
account for viral load. If we assume that in a sample of 1,000 PWID from the Northern 
region of the country, 11% are HIV positive and 10% of these are recent on the LAg Avidity, 
HIV incidence would be 2.4% (CI: 0.9–3.8) using no PFR, 1.9% (CI: 0.4–3.5) using our 
observed PFR 2.7%, and 2.1% (CI: 0.6–3.6) using our observed residual PFR of 2.0%. 
Similar calculations for the BED-CEIA would yield an incidence of 2.2% (CI: 0.8–3.6) 
using no PFR and 1.5%(CI: 0.2–2.9) using our observed PFR 3.4% and 1.7% (CI: 0.3–3.0). 
The minimal differences observed between the incidence estimates after further exclusion of 
low viral loads in our study and in the above example suggest that for this hypothetical 
PWID population example in Vietnam, the inclusion of viral load in the recent infection 
testing algorithm may not be warranted. Finally, similar to other evaluations, we found that 
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specimens classified as false recent by the LAg-Avidity EIA assay were also false recent on 
the BED-CEIA12,15 and a two-test algorithm using the BED-CEIA as the screening assay 
followed by LAg-Avidity EIA as the confirmatory assay would result in a PFR of 2.2%, 
which is not significantly different compared to LAg-Avidity EIA alone.
There were statistically significant regional differences in the BED-CEIA and LAg-Avidity 
EIA PFR between north and south Vietnam and differences by northern clinic site. The 
differences in age, CD4 count, and duration of HIV infection in the north compared to the 
south confirm regional differences between the populations of HIV-infected people in care. 
All false-recent cases were HIV-1 subtype AE, the most dominant subtype in the region, 
confirming that HIV-1 clade did not contribute to observed regional differences in the PFR. 
However, there were differences in the PFRs by clinic site suggesting differing populations 
by OPCs.
This study was subject to several limitations. The majority of the misclassified specimens 
were from the two northern clinics. In combination, this suggests there may be clinic-
specific biases related to data quality from these clinics. This study was not powered to 
detect differences in the PFR by site of enrollment and demographic and clinical 
characteristics in the northern and southern regions separately. Furthermore, determining a 
site-specific PFR is not feasible given the large sample size needed to determine a PFR. 
Participants were recruited at the point of care at the HIV clinic, and therefore, results are 
not generalizable to the entire population of persons living with HIV in Vietnam. 
Furthermore, the southern region was represented only by one province, Ho Chi Minh City, 
whereas in the northern region, samples were collected from three provinces. Although no 
population level samples are available to determine a more generalizable PFR, our results 
are consistent with results from a study in China showing a LAg-Avidity EIA FRR of 1.1% 
and HCMC showing a BED-CEIA FRR of 1.7%. Finally, since data on OIs were limited, we 
were unable to assess possible associations between OI and false-recent classification that 
may be associated with false-recent misclassification due to advanced HIV status and 
decreased antibody response.
We are continuing to examine the application of the LAg-Avidity EIA in cross-sectional 
population in Vietnam and elsewhere to assess its utility in providing accurate incidence 
estimates and trends over time. Use of the PFR may result in an over, under, or even a 
negative estimate of incidence if the PFR is not derived from a population similar to the one 
that is being surveyed for incidence estimation or if the PFR is elevated due to sample bias 
(e.g., ARV use). Therefore, caution should be taken during study design for HIV incidence 
estimation and sample collection to minimize potential biases. As suggested by the WHO 
recommendations, a multiassay algorithm that incorporates testing for viral load at a 
minimum, and testing for ARV drugs where feasible, should be conducted to minimize false 
recency.34 The data presented in this study are consistent with a previously described low 
PFR for the LAg-Avidity EIA and demonstrate a low PFR for the BED-CEIA.12 Therefore, 
we believe that both assays have the potential to provide accurate HIV-1 incidence in cross-
sectional populations in Vietnam. However, when ARV and viral load testing are not 
available, because the PFR was slightly lower with the LAg-Avidity EIA (1.7% versus 
2.3%with the BED-CEIA without VL testing), the LAg-Avidity EIA should be used for 
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cross-sectional incidence assays and for impact evaluation of combination prevention 
programs being implemented to reduce the transmission of HIV in Vietnam. Finally, at this 
time we do not know if the PFR is stable over time and more research is needed to better 
understand if there is variability to the PFR as HIV epidemic change.
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FIG. 1. 
The PFR for the LAg-Avidity EIA and the BED-CEIA by clinic site, Vietnam 2009–2010. 
PFR, proportion false recent; BED-CEIA, BED capture enzyme immunoassay.
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FIG. 2. 
PFR algorithm for the LAg-Avidity EIA and BED-CEIA excluding ARV and ARV plus viral 
load, Vietnam 2009–2010. ARV, antiretroviral.
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Table 1
Characteristics of PFR Study Sample Stratified by Region, Vietnam 2009–2010
Characteristic
Total (n, %)
N = 1813
North (n, %)
N = 942
South (n, %)
N = 871 p-value
Age group (years) <.001
  18–24 201 (11.1) 68 (7.2) 133 (15.3)
  25–34 1,182 (65.2) 585 (62.1) 597 (68.5)
  35–44 355 (19.6) 234 (24.8) 121 (13.9)
  45–54 67 (3.7) 50 (5.3) 17 (2.0)
  55+ 8 (0.4) 5 (0.5) 3 (0.3)
Sex <.001
  Male 968 (53.7) 558 (59.8) 410 (47.1)
  Female 836 (46.3) 375 (40.2) 461 (52.9)
  Missing 9 (0.5) 9 (1.0)
Duration since documented <.001
  HIV positive test result (years)
  1–2 853 (47.1) 408 (43.3) 445 (51.1)
  2–3 569 (31.2) 243 (25.8) 326 (37.4)
  >3 391 (21.6) 292 (30.9) 100 (11.5)
CD4 cell count category <.001
  <50 cells/mm3 146 (8.1) 115 (12.3) 31 (3.6)
  50–199 cells/mm3 256 (14.2) 151 (16.2) 105 (12.2)
  200–349 cell/mm3 458 (25.3) 211 (22.5) 247 (28.4)
  350–499 cell/mm3 514 (28.4) 257 (27.4) 257 (29.6)
  > = 500 cell/mm3 434 (24.0) 205 (21.8) 229 (26.4)
  Missing 5 (0.2) 3 (0.3) 2 (0.2)
Opportunistic infections N = 1,049 N = 938 N = 111
  TB 117 (11.2) 88 (9.4) 29 (26.1) <.001
  PCP 15 (1.4) 15 (1.6) 0 (0) .39
  Candida 90 (8.5) 79 (8.4) 11 (9.9) .59
  Herpes Zoster 28 (2.4) 22 (2.4) 6 (5.4) .04
  Chronic Diarrhea 67 (6.4) 61 (6.5) 6 (5.5) .84
Risk group, (n/N, %) N = 1,727 N = 906 N = 821
  IDU 739 (42.8) 437 (48.2) 302 (36.8) <.001
  MSM 7 (0.4) 6 (0.7) 1 (0.1) .13
  FSW 9 (0.5) 5 (0.6) 4 (0.5) 1.00
IDU, injection drug users; FSW, female sex workers; MSM, men who have sex with men; PFR, proportion false recent.
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Table 2
PFR for the LAg-Avidity EIA and BED-CEIA With and Without Low Viral Load Specimens and by Region, 
Vietnam 2009–2010
Method
Total false
recents n/N
PFR%
(95% CI)
Total false recents
after excluding low
viral load specimens n/N
PFR after
exclusion% (95% CI)
BED-CEIA 41/1,813 2.3% (1.7–3.1)a 31/1,803 1.7% (1.2–2.4)
  North 32/942 3.4% (2.4–4.8) 26/936 2.8% (1.9–4.0)
  South 9/871 1.0% (0.5–2.0) 5/867 0.6% (0.2–1.3)
LAg-Avidity EIA 31/1,813 1.7% (1.2–2.4)a 22/1,791 1.2% (0.8–1.9)
  North 25/942 2.7% (1.8–3.9) 19/936 2.0% (1.3–3.1)
  South 6/871 0.7% (0.3–1.5) 3/868 0.3% (0.1–1.1)
a
McNemar p-value .06.
95% confidence interval calculated using Wilson score interval procedure.
BED-CEIA, BED capture enzyme immunoassay.
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Table 3
Proportion False Recent on the BED-CEIA Assay by Select Demographic and Clinical Characteristics and by 
Region, Vietnam 2009–2010
Characteristic
Total
(n/N, %)
North
(n/N, %)
South
(n/N, %) p-value
Proportion false recent 41/1,813 (2.3) 32/942 (3.4) 9/871 (1.0) <.001
Age group (years) .80
  18–24 5/201 (2.5) 3/68 (4.4) 2/133 (1.5)
  25–34 33/1,182 (2.8) 26/585 (4.4) 7/597 (1.2)
  35–44 2/355 (0.6) 2/234 (0.9) 0/121 (0)
  45–54 1/67 (1.5) 1/50 (2.0) 0/17 (0)
  55+ 0/8 (0) 0/5 (0.0) 0/3 (0)
Sex .02
  Male 20/968 (2.1) 19/558 (3.4) 1/410 (0.2)
  Female 21/836 (2.5) 13/375 (3.5) 8/461 (1.7)
Documented duration since last .89
  HIV positive test result (years)
  1–2 20/853 (2.3) 15/408 (3.7) 5/445 (1.1)
  2–3 9/569 (1.6) 7/243 (2.9) 2/326 (0.6)
  3+ 12/391 (3.1) 10/291 (3.4) 2/100 (2.0)
D4 cell count category .05
  <50 cells/mm3 5/146 (3.4) 5/115 (4.3) 0/31 (0)
  50–199 cells/mm3 3/256 (1.2) 1/151 (0.7) 2/105 (1.9)
  200–349 cell/mm3 7/458 (1.5) 7/211 (3.3) 0/247 (0)
  350–499 cell/mm3 14/514 (2.7) 12/257 (4.7) 2/257 (0.8)
  > = 500 cell/mm3 12/434 (2.8) 7/205 (3.4) 5/229 (2.2)
Opportunistic infections NA
  TB 2/117 (1.7) 2/88 (2.3) 0/29 (0)
  PCP 0/15 (0) 0/15 (0) 0/0 (0)
  Candida 4/90 (4.4) 4/79 (5.1) 0/11 (0)
  Herpes Zoster 0/28 (0) 0/22 (0) 0/6 (0)
  Chronic Diarrhea 1/67 (1.5) 1/61 (1.6) 0/6 (0)
Risk group
  IDU 16/739 (2.2) 14/437 (3.2) 2/302 (0.7) .14
  MSM 0/7 (0) 0/6 (0) 0/1 (0)
  FSW 0/9 (0) 0/5 (0) 0/4 (0)
NA, not applicable.
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Table 4
Proportion False Recent on the LAg-Avidity EIA Assay by Select Demographic and Clinical Characteristics 
and by Region, Vietnam 2009–2010
Characteristic
Total
(n/N, %)
North
(n/N, %)
South
(n/N, %) p-value
Proportion false recent 31/1,813 (1.7) 25/942 (2.7) 6/871 (0.7) .001
Age group (years) 1.00
  18–24 4/201 (2.0) 3/68 (4.4) 1/133 (0.8)
  25–34 25/1,182 (2.1) 20/585 (3.4) 5/597 (0.8)
  35–44 1/355 (0.3) 1/234 (0.4) 0/121 (0)
  45–54 1/67 (1.5) 1/50 (2.0) 0/17 (0)
  55+ 0/8 (0) 0/5 (0) 0/3 (0)
Sex .65
  Male 15/968 (1.5) 13/558 (2.3) 2/410 (0.5)
  Female 16/836 (1.9) 12/375 (3.2) 4/461 (0.9)
Documented duration since last .69
  HIV positive test result (years)
  1–2 17/853 (2.0) 13/408 (3.2) 4/445 (0.9)
  2–3 9/569 (1.6) 7/243 (2.9) 2/326 (0.6)
  3+ 5/391 (1.3) 5/291 (1.7) 0/100 (0)
CD4 cell count category
  <50 cells/mm3 2/146 (1.4) 2/115 (1.7) 0/31 (0)
  50–199 cells/mm3 2/256 (0.8) 2/151 (1.3) 0/105 (0) .50
  200–349 cell/mm3 6/458 (1.3) 6/211 (2.8) 0/247 (0)
  350–499 cell/mm3 10/514 (1.9) 8/257 (3.1) 2/257 (0.8)
  > = 500 cell/mm3 11/434 (2.5) 7/205 (3.4) 4/229 (1.7)
Opportunistic infections NA
  TB 1/117 (0.9) 1/88 (1.1) 0/29 (0)
  PCP 0/15 (0) 0/15 (0) 0/0 (0)
  Candida 1/90 (1.1) 1/79 (1.3) 0/11 (0)
  Herpes Zoster 0/28 (0) 0/22 (0) 0/6 (0)
  Chronic Diarrhea 0/67 (0) 0/61 (0) 0/6 (0)
Risk group
  IDU 9/739 (1.2) 8/437 (1.8) 1/302 (0.3) .63
  MSM 0/7 (0) 0/6 (0) 0/1 (0)
  FSW 0/9 (0) 0/5 (0) 0/4 (0)
NA, not applicable.
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